Sign Out
To date there is no available information on safety of use in pregnant women. Based on pre-clinical findings, oxaliplatin is likely to be lethal and/or teratogenic to the human foetus at the recommended therapeutic dose, and is consequently not recommended during pregnancy and should only be considered after suitably appraising the patient of the risk to the foetus and with the patient's consent.
Excretion in breast milk has not been studied. Breast-feeding is contra-indicated during oxaliplatin therapy.
